A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
NCT ID: NCT06884085
Last Updated: 2025-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
70 participants
INTERVENTIONAL
2025-07-12
2025-08-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of AD-223
NCT06052748
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
NCT06671392
A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers
NCT05077462
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
NCT02603809
The Effects of Dietary Nitrate in Patients With Hypertensive Kidney Injury
NCT07290842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence A (RT)
Period 1: Reference (Co-administration of AD-227A and AD-227B), Period 2: Test (AD-227)
Co-administration of AD-227A and AD-227B
Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral
Administration of AD-227
Administration of AD-227 1Tab., Per Oral
Sequene B (TR)
Period 1: Test (AD-227), Period 2: Reference (Co-administration of AD-227A and AD-227B)
Co-administration of AD-227A and AD-227B
Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral
Administration of AD-227
Administration of AD-227 1Tab., Per Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Co-administration of AD-227A and AD-227B
Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral
Administration of AD-227
Administration of AD-227 1Tab., Per Oral
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-227BE-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.